What Long-Term Data Are Available for Jakafi® (ruxolitinib)?

Read below for Selected Safety Information. Hematologist-oncologist Gary Grad, MD, reviews the results of two research studies that explored spleen size and analyzed overall survival in adults with intermediate-2 or high-risk myelofibrosis (MF). Patients were monitored for up to 3 years to determine overall survival. Dr. Grad recommends talking with your Healthcare Professional to help you understand the results of the studies.

This video is intended for informational use only, and is not designed to replace the medical advice of your Healthcare Professional.

Jakafi® (ruxolitinib) is used to treat adults with intermediate- or high-risk myelofibrosis (MF).
Selected Safety Information
Jakafi can cause serious side effects including low blood counts and infection. Some people who take Jakafi have developed certain types of non‐melanoma skin cancers. Increases in blood cholesterol levels can also occur. In patients who took another JAK inhibitor to treat rheumatoid arthritis, there was an increased risk of potentially fatal cardiovascular events like heart attack or stroke in patients with risk factors for these events who smoke now or smoked in the past, as well as an increased risk of blood clots in legs or lungs and new (secondary) cancers like lymphoma, especially in patients who smoke now or smoked in the past. The most common side effects of Jakafi for certain types of MF and polycythemia vera include: low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea. Call your doctor for medical advice about side effects.

To learn more about these and other risks, please read the Important Safety Information at https://www.jakafi.com/.

Please see the Full Prescribing Information at https://www.jakafi.com/pi/pi, which includes a more complete discussion of the risks associated with Jakafi.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
You may also report side effects to Incyte Medical Information at 1-855-463-3463.

Sponsored by Incyte Corporation. Jakafi is a registered trademark of Incyte.
© 2020, Incyte Corporation. MAT-JAK-03742 01/22